MedTrace Logo

Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism

NCT02095925 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2017-01-18

No results posted yet for this study

Summary

Cancer patients are at increased risk of deep venous thrombosis and pulmonary embolism, collectively termed venous thromboembolism (VTE). Risk assessment scores for VTE in cancer patients have been previously developed by the groups of Khorana and Vienna CATS. However, routine thromboprophylaxis for ambulatory cancer patients based on these scores is currently not recommended. In the investigators prospective, observational cohort study, the investigators aim to identify cancer patients at high risk for VTE based on clinical characteristics, coagulation biomarkers and the coagulant activity of tissue factor bearing microparticles.

Conditions

Sponsors & Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER

  • Amsterdam UMC, location VUmc

    collaborator OTHER

  • University Medical Center Groningen

    collaborator OTHER

  • Slotervaart Hospital

    collaborator OTHER

  • Hôpital Louis Mourier

    collaborator OTHER

  • Università degli Studi 'G. d'Annunzio' Chieti e Pescara

    collaborator OTHER

  • Instituto Nacional de Cancerologia de Mexico

    collaborator OTHER

  • Harry R. Buller

    lead OTHER

Principal Investigators

  • Harry R Buller, MD PhD · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2016-06-30
Completion
2017-01-31

Countries

  • France
  • Italy
  • Mexico
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02095925 on ClinicalTrials.gov